[1]de Alwis NM, Day CP.Non-alcoholic fatty liver disease:themist gradually clears[J].J Hepatol, 2008, 48 (Suppl 1) :104-112.
|
[2]Farrell GC, Chitturi S, Lau GK, et al.Guidelines for theassessment and management of non-alcoholic fatty liverdisease in the Asia-Pacific region:executive summary[J].Gastroenterol Hepatol, 2007, 22 (6) :775-777.
|
[3]Laubner K, Kieffer TJ, Lam NT, et al.Inhibition of preproi-nsulin gene expression by leptin induction of suppressor ofcytokine signaling 3 in pancreatic bete-cells[J].Diabetes, 2005, 54 (12) :3410-3417.
|
[4]Sachithanandan N, Fam BC, Fynch S, et al.Liver-specificsuppressor of cytokine signaling-3 deletion in mice enhanceshepatic insulin sensitivity and lipogenesis resulting in fatty liverand obesity[J].Hepatology, 2010, 50 (5) :1632-1642.
|
[5]Li YL, Yang M, Meng XD, et al.The relationship of leptinand adiponectin with insulin resistance in nonalcoholic fattyliver disease[J].Zhonghua Gan Zang Bing Za Zhi, 2010, 18 (6) :459-462.
|
[6]Antal M, Regoly MA.New approach in the interpretation ofadipose tissue[J].Orv Hetil, 2010, 151 (31) :1252-1260.
|
[7]Hui JM, Hodge A, Farrell GC, et al.Beyond insulin resistancein NASH:TNF-alpha or adiponectin?[J].Hepatology, 2004, 40 (1) :46-54.
|
[8]Lee YS, Cho YK, Pae JC, et al.The relationship betweenserum adiponectin level and serum alanine aminotransferaseelevation in Korean male with nonalcoholic fatty liverdisease[J].Korean J Hepatol, 2006, 12 (2) :221-229.
|
[9]Tomita K, Oike Y, Teratani T, et al.Hepatic AdipoR2signaling plays a protective role against progression ofnonalcoholic steatohepatitis in mice[J].Hepatology, 2008, 48 (2) :458-473.
|
[10]Yoneda M, Iwasaki T, Fujita K, et al.Hypoadiponectinemiaplays a crucial role in the development of nonalcoholicfatty liver disease in patients with type 2 diabetes mellitusindependent of visceral adipose tissue[J].Alcohol Clin ExpRes, 2007, 31 (Suppl1) :S15-21.
|
[11]Martin SS, Qasim A, Reilly MP.Leptin resistance:a possibleinterface of inflammation and metabolism in obesity-relatedcardiovascular disease[J].J Am Coll Cardiol, 2008, 52 (15) :1201-1210.
|
[12]Munzberg H, Bjornholm M, Bates SH, et al.Leptin receptoraction and mechonisms of leptin resistance[J].Cell Mol LifeSci, 2005, 62 (6) :642-652.
|
[13]Polyzos SA, Kountouras J, Zavos C, et al.The PotentialAdverse Role of Leptin Resistance in Nonalcoholic FattyLiver Disease:A Hypothesis Based on Critical Review ofLiterature[J].Clin Gastroenterol, 2010, 45 (1) :50-54.
|
[14]Canbakan B, Tahan V, Balci H, et al.Leptin in nonalcoholicfatty liver disease[J].Ann Hepatol, 2008, 7 (3) :249-254.
|
[15]Saxena NK, Titus MA, Ding X, et al.Leptin as a novelprofibro-genic cytokine in hepatic stellate cells:mitogenesisand inhibition of apoptosis mediated by extracellularregulated kinase (Erk) and Akt phosphorylation[J].FASEB J, 2004, 18 (13) :1612-1614.
|
[16]Wang J, Brymora J, George J.Roles of adipokines in liverinjury and fibrosis[J].Expert Rev Gastroenterol Hepatol, 2008, 2 (1) :47-57.
|
[17]Yoon D, Lee SH, Park HS, et al.Hypoadiponectinemia andinsulin resistance are associated with nonalcoholic fatty liverdisease[J].Korean Med Sci, 2005, 20 (3) :421-426.
|
[18]Aygun C, Senturk O, Hulagu S, et al.Serum levels ofhepatoprotective peptide adiponectin in non-alcoholicfatty liver disease[J].Eur J Gastroenterol Hepatol, 2006, 18 (2) :175-180.
|
[19]Tsatsanis C, Zacharioudaki V, Androulidaki A, et al.Adiponectin induces TNF-alpha and IL-6 in macrophagesand promotes tolerance to itself and other pro-inflammatorystimuli[J].Biochem Biophys Res Commun, 2005, 335 (4) :1254-1263.
|
[20]Hindle AK, Edwards C, Mendonsa A, et al.Adiponectin butnot leptin is involved in early hepatic disease in morbidlyobese patients[J].Surg Endosc, 2010, 24 (7) :1547-1551.
|